000 | 01917 a2200553 4500 | ||
---|---|---|---|
005 | 20250513121734.0 | ||
264 | 0 | _c19970731 | |
008 | 199707s 0 0 eng d | ||
022 | _a0021-9738 | ||
024 | 7 |
_a10.1172/JCI119514 _2doi |
|
040 |
_aNLM _beng _cNLM |
||
100 | 1 | _aHershberg, R M | |
245 | 0 | 0 |
_aIntestinal epithelial cells use two distinct pathways for HLA class II antigen processing. _h[electronic resource] |
260 |
_bThe Journal of clinical investigation _cJul 1997 |
||
300 |
_a204-15 p. _bdigital |
||
500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S. | ||
650 | 0 | 4 |
_aCD4-Positive T-Lymphocytes _ximmunology |
650 | 0 | 4 |
_aCathepsin B _xmetabolism |
650 | 0 | 4 | _aCathepsin H |
650 | 0 | 4 | _aCathepsin L |
650 | 0 | 4 |
_aCathepsins _xmetabolism |
650 | 0 | 4 | _aColonic Neoplasms |
650 | 0 | 4 |
_aCysteine Endopeptidases _xmetabolism |
650 | 0 | 4 | _aDNA Primers |
650 | 0 | 4 | _aDimerization |
650 | 0 | 4 | _aEndopeptidases |
650 | 0 | 4 |
_aHLA-D Antigens _xbiosynthesis |
650 | 0 | 4 |
_aHLA-DQ Antigens _xbiosynthesis |
650 | 0 | 4 |
_aHLA-DR Antigens _xbiosynthesis |
650 | 0 | 4 | _aHistocompatibility Antigens Class II |
650 | 0 | 4 | _aHumans |
650 | 0 | 4 |
_aInterferon-gamma _xpharmacology |
650 | 0 | 4 |
_aIntestinal Mucosa _xdrug effects |
650 | 0 | 4 |
_aLeupeptins _xpharmacology |
650 | 0 | 4 | _aPolymerase Chain Reaction |
650 | 0 | 4 |
_aProtease Inhibitors _xpharmacology |
650 | 0 | 4 |
_aRecombinant Proteins _xbiosynthesis |
650 | 0 | 4 | _aTransfection |
650 | 0 | 4 | _aTumor Cells, Cultured |
700 | 1 | _aFramson, P E | |
700 | 1 | _aCho, D H | |
700 | 1 | _aLee, L Y | |
700 | 1 | _aKovats, S | |
700 | 1 | _aBeitz, J | |
700 | 1 | _aBlum, J S | |
700 | 1 | _aNepom, G T | |
773 | 0 |
_tThe Journal of clinical investigation _gvol. 100 _gno. 1 _gp. 204-15 |
|
856 | 4 | 0 |
_uhttps://doi.org/10.1172/JCI119514 _zAvailable from publisher's website |
999 |
_c9182585 _d9182585 |